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OBJECTIVES: To determine when re-censoring should be incorporated in statistical analyses 
undertaken to adjust for treatment switching in randomised controlled trials, and to demonstrate 
the utility of inverse probability weighting (IPW) as an alternative to re-censoring. Treatment 
switching often has a crucial impact on estimates of the effectiveness and cost-effectiveness of new 
oncology treatments. Switching adjustment methods such as rank preserving structural failure time 
models (RPSFTM) and two-ƐƚĂŐĞĞƐƚŝŵĂƚŝŽŶĞƐƚŝŵĂƚĞ ?ĐŽƵŶƚĞƌĨĂĐƚƵĂů ? ?ŝ ?Ğ ?ŝŶƚŚĞĂďƐĞŶĐĞŽĨ
switching) survival times and incorporate re-censoring to guard against informative censoring in the 
counterfactual dataset. However, re-censoring often involves a loss of longer term survival 
information which is problematic when estimates of long-term survival effects are required. 
METHODS: A simulation study was conducted, testing RPSFTM and two-stage adjustment methods 
with and without re-censoring, and with IPW in place of re-censoring, across scenarios with various 
switch proportions and sizes and time dependencies of the treatment effect. Methods were 
assessed according to their estimation of true restricted mean survival (in the absence of switching) 
at the end of trial follow-up. RESULTS: RPSFTM analyses that incorporated re-censoring were prone 
to bias when the treatment effect decreased over time  ? overestimating the treatment effect by 
approximately 311% in these scenarios, compared to bias of approximately 02% for RPSFTM and 
two-stage analyses that did not incorporate re-censoring. Two-stage analyses usually overestimated 
the treatment effect when re-censoring was incorporated and consistently underestimated the 
treatment effect when re-censoring was not incorporated. Using IPW in place of re-censoring 
resulted in low levels of bias when the censoring proportion and switching proportion were 
relatively low (both approximately 25%). CONCLUSIONS: Re-censoring should not always be 
incorporated in adjustment analyses when the objective is to estimate the long-term treatment 
effect. Conducting analyses with and without re-censoring may provide useful information on the 
size of the true treatment effect. 
